Protecting America from Seasonal and Pandemic Influenza Act of 2026
- Bill Number
- H.R. 8447
- Origin Chamber
- House
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-04-22: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Last Updated
- 2026-05-21T16:31:14Z
AI-Generated Summary
Purpose
The Protecting America from Seasonal and Pandemic Influenza Act of 2026 (H.R. 8447) aims to enhance U.S. preparedness for seasonal and pandemic influenza by accelerating vaccine and therapeutic development, strengthening domestic supply chains, improving diagnostics and access, combating vaccine hesitancy, and providing sustained funding.
Key Provisions
- National Goals and Plans:
- Deliver first doses of finished influenza vaccine within 12 weeks of a pandemic strain's emergence (within 3 years).
- Develop a universal influenza vaccine (within 10 years).
- Publish detailed implementation plans by HHS, ASPR, BARDA, and NIH.
- Development and Manufacturing:
- Establish public-private partnerships to bolster domestic supply chains (including ingredients, fill-finish, and supplies like needles).
- Fully implement the National Influenza Vaccine Modernization Strategy (2020-2030) with annual reports to Congress.
- Support innovative technologies for vaccines, antivirals, diagnostics, and antibody products.
- Diagnostics and Therapeutics:
- Prioritize pathogen-agnostic detection tools, point-of-care/self-tests, and supply chain resiliency plans.
- Modernize potency assays to speed vaccine evaluation by 6 weeks.
- Expand Strategic National Stockpile with antivirals, tests, and countermeasures; monitor and distribute supplies.
- Access and Communication:
- Partnerships to combat misinformation, targeting vulnerable groups (e.g., elderly, minorities, rural communities).
- Demonstration projects for communications, test-to-treat in high-risk settings, and pharmacy administration grants.
- Annual reports on vaccine confidence and access plans for high-risk/underserved populations.
- Funding Authorizations (FY 2027 onward, annual unless specified):
- $335 million for pandemic influenza programs (FY 2027-2031).
- Over $3.4 billion total across CDC, SNS, NIH, ASPR programs (e.g., $1B for Strategic National Stockpile, $270M for universal vaccine research).
Significant Changes to Existing Law
- Public Health Service Act Amendments:
- Expands ASPR duties to include influenza-specific countermeasures and strategy implementation.
- Adds BARDA "pandemic influenza medical countermeasures program" for R&D, stockpiles, and drills.
- Authorizes new appropriations and requires stockpile testing/lifecycle management.
- Budget Mechanisms:
- Designates "health defense operations" funding as exempt from certain spending caps (Balanced Budget Act).
- Creates "professional bypass budgets" for CDC, NIH, and ASPR to submit directly to Congress/President.
Potential Impacts
- Government Agencies: HHS sub-agencies (CDC, NIH, BARDA, ASPR) gain mandates, resources, and reporting requirements, improving coordination and rapid response capabilities.
- Citizens: Reduced influenza deaths, hospitalizations, and costs through faster vaccines/tests/treatments; better access for vulnerable groups; increased vaccine confidence.
- International Relations: Strengthens U.S. biotech leadership, reduces reliance on foreign supply chains (e.g., China), enhancing national security.
Main Stakeholders Affected
- Federal Agencies: HHS, CDC, NIH, BARDA, ASPR, FDA, IHS, VA.
- Private Sector: Vaccine/therapeutic manufacturers, pharmacies, distributors.
- State/Local Entities: Health departments, receiving grants and stockpile guidance.
- Public: Vulnerable populations (elderly, children, minorities, rural/Tribal communities, high-risk patients); general public via awareness campaigns.
- Others: First responders, health care workers, long-term care facilities.
Notable Legal, Constitutional, or Political Implications
- Legal: Establishes enforceable national goals, mandatory plans/reports, and demonstration projects; no mandates on individuals (focuses on government action).
- Constitutional: Aligns with federal public health powers (e.g., interstate commerce, national defense); bypass budgets may streamline funding but require congressional designation.
- Political: Frames influenza preparedness as national security issue; significant new spending (~$3-4B/year) could spark budget debates; emphasizes domestic manufacturing amid global tensions.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (5)
Rep. Ross, Deborah K. [D-NC-2], Rep. Stansbury, Melanie A. [D-NM-1], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Barragán, Nanette Diaz [D-CA-44], Rep. Thanedar, Shri [D-MI-13]
Recent Actions
- 2026-04-22: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2026-04-22: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2026-04-22: Introduced in House
- 2026-04-22: Introduced in House
Bill Versions
- Protecting America from Seasonal and Pandemic Influenza Act of 2026 — issued 2026-04-22 — PDF (27 pages)